TY - JOUR
T1 - Insights into the role of Helicobacter pylori infection in preeclampsia: from the bench to the bedside
AU - Tersigni, Chiara
AU - Franceschi, Francesco
AU - Todros, Tullia
AU - Cardaropoli, Simona
AU - Scambia, Giovanni
AU - Di Simone, Nicoletta
PY - 2014
Y1 - 2014
N2 - Preeclampsia (PE) is defined as a hypertensive and coagulative disorder affecting about
2–8% of all pregnancies and is one of the main causes of maternal and fetal morbidity
and mortality. Despite the great amount of studies run in this field, little is known
about the precise pathogenic mechanisms behind PE. While endothelial and trophoblast
dysfunctions, exaggerated inflammatory response, and hypercoagulative state have been
shown to play a key role in the occurrence of PE, the primary trigger is still unknown. One
of the hypotheses is that some infectious agents may represent a trigger for PE onset.
Consistently, higher seroprevalence of Helicobacter pylori (HP) infection, a Gram-negative
bacterium with a specific tropism for human gastric mucosa, has been shown in women
with PE. Even tighter association has been found between PE and infection with cytotoxinassociated
gene-A (CagA)-positive strains of HP. Recent in vitro studies have shown that
anti-CagA antibodies cross-react with human trophoblast cells and determine a functional
impairment in terms of cell invasiveness, thus, providing the first pathogenic model of
HP infection-mediated placental damage. Since in the early process of implantation and
placental development, trophoblast invasion of maternal decidua is a crucial step, the proposed
autoimmune mechanism induced by HP infection, negatively interfering with the
fetal side of the early developing placenta, may represent a mechanism explaining the
higher seropositivity for HP infection among PE women. However, the contribution of HP
infection to the pathogenesis of PE or to the worsening of its clinical presentation need
to be further investigated as well as the possible impact of pre-pregnancy screening and
eradication of HP infection on the incidence of the syndrome
AB - Preeclampsia (PE) is defined as a hypertensive and coagulative disorder affecting about
2–8% of all pregnancies and is one of the main causes of maternal and fetal morbidity
and mortality. Despite the great amount of studies run in this field, little is known
about the precise pathogenic mechanisms behind PE. While endothelial and trophoblast
dysfunctions, exaggerated inflammatory response, and hypercoagulative state have been
shown to play a key role in the occurrence of PE, the primary trigger is still unknown. One
of the hypotheses is that some infectious agents may represent a trigger for PE onset.
Consistently, higher seroprevalence of Helicobacter pylori (HP) infection, a Gram-negative
bacterium with a specific tropism for human gastric mucosa, has been shown in women
with PE. Even tighter association has been found between PE and infection with cytotoxinassociated
gene-A (CagA)-positive strains of HP. Recent in vitro studies have shown that
anti-CagA antibodies cross-react with human trophoblast cells and determine a functional
impairment in terms of cell invasiveness, thus, providing the first pathogenic model of
HP infection-mediated placental damage. Since in the early process of implantation and
placental development, trophoblast invasion of maternal decidua is a crucial step, the proposed
autoimmune mechanism induced by HP infection, negatively interfering with the
fetal side of the early developing placenta, may represent a mechanism explaining the
higher seropositivity for HP infection among PE women. However, the contribution of HP
infection to the pathogenesis of PE or to the worsening of its clinical presentation need
to be further investigated as well as the possible impact of pre-pregnancy screening and
eradication of HP infection on the incidence of the syndrome
KW - Helicobacter pylori
KW - preeclampsia
KW - Helicobacter pylori
KW - preeclampsia
UR - http://hdl.handle.net/10807/61062
U2 - 10.3389/fimmu.2014.00484
DO - 10.3389/fimmu.2014.00484
M3 - Article
SN - 1664-3224
SP - 1
EP - 4
JO - Frontiers in Immunology
JF - Frontiers in Immunology
ER -